4 results about "Coagulation factor VII" patented technology

The invention discloses a hemostatic peptide capable of targeting to a bleeding focus as well as a preparation method and application of the hemostatic peptide, and the hemostatic peptide is characterized in that the amino acid sequence of the hemostatic peptide is RKLFFVRTA. According to the present invention, the key amino acid sequence combined with TF in the blood coagulation factor VII (FVII) is adopted as the basis for modification, the exposed TF (blood coagulation starting factor) after the blood vessel injury is specially identified, the specific expression of the TF at the bleeding site is adopted to achieve the precise targeting, the interference on the normal blood vessel is reduced, and the unnecessary thrombus risk is reduced from the source.

The present application relates to saRNA and oligonucleotide modulators for the prevention or treatment of FVII related diseases, conditions or disorders and uses thereof, such as diseases caused by or related to insufficient expression of the FVII gene or bleeding complications caused by hemophilia with inhibitors. The present application also relates to a pharmaceutical composition comprising an oligonucleotide modulator and a method of preventing or treating FVII-related diseases, conditions or disorders induced by insufficient FVII levels with the oligonucleotide modulator disclosed herein.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor VII, CA 19-9, Insulin-like growth factor-binding protein 7, C-X-C motif chemokine 6, and C-C motif chemokine 13 as diagnostic and prognostic biomarkers in renal injuries.